| [1] |
Bray F, Ferlay J,Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J]. Int J Cancer, 2019, 144(8): 1941-1953.
|
| [3] |
Galanakis N, Kehagias E, Matthaiou N, et al. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review[J]. Hepat Oncol, 2018, 5(2): HEP07.
|
| [4] |
Song PP, Cai YL, Tang HW, et al. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017[J]. BioScience Trends, 2017, 11(4): 389-398.
|
| [5] |
陈孝平. 外科学(第2版)[M]. 北京: 人民卫生出版社, 2010: 620-622.
|
| [6] |
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109.
|
| [7] |
Merkle EM, Zech CJ, Bartolozzi C, et al. Consensus report from the 7thInternational Forum for Liver Magnetic Resonance Imaging[J]. Eur Radiol, 2016, 26(3): 674-682.
|
| [8] |
Zheng J, Li J, Cui X, et al. Comparison of diagnostic sensitivity of C-arm CT, DSA and CT in detecting smallHCC[J].Hepatogastroenterology, 2013, 60(126): 1509-1512.
|
| [9] |
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354.
|
| [10] |
Chalian H, Tore HG, Horowitz JM, et al. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0[J]. Radiographics, 2011, 31(7): 2093-2105.
|
| [11] |
Lee JW, Oh JK, Chung YA, et al. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study[J]. J Nucl Med, 2016, 57(4): 509-516.
|
| [12] |
中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1): 1-20.
|
| [13] |
Rodriguez-Peralvarez M, Luong TV, Andreana L, et al.A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1): 325-39.
|
| [14] |
中国抗癌协会肝癌专业委员会，中华医学会肝病学分会肝癌学组，中国抗癌协会病理专业委员会. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 中华肝胆外科杂志, 2015, 21(3): 145-151.
|
| [15] |
Ayuso C,Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma(HCC): current guidelines[J].Eur J Radiol, 2018, 101: 72-81.
|
| [16] |
美国东部肿瘤协作组. 体能状态评分ECOG评分法[J]. 中华普通外科学文献(电子版), 2012, 6(6): 64-64,
|
| [17] |
郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 208-213.
|
| [18] |
郑加生. CT引导肝肿瘤消融治疗学[M]. 第一版. 北京: 人民卫生出版社, 2011: 1-8.
|
| [19] |
中华医学会放射学分会介入学组. 经皮肝脏肿瘤射频消融治疗操作规范专家共识[J]. 中华放射学杂志, 2012, 46(7): 581-585.
|
| [20] |
国家卫计委肿瘤消融治疗技术管理规范专家组. 肿瘤消融治疗技术管理规范(2017年版)[J]. 中华医学杂志, 2017, 97(31): 2416-2417.
|
| [21] |
王洋，范承启，邵成. 肝癌微波消融治疗的新进展[J]. 医学影像学杂志, 2019, 29(3): 491-494.
|
| [22] |
Aghayev A, Tatli S. The use of cryoablation in treating liver tumors[J]. Expert Rev Med Devices, 2014, 11(1): 41-52．
|
| [23] |
周赟，龚建平，王春. 高强度聚焦超声提高机体抗肿瘤免疫的相关机制[J]. 中国现代普通外科进展, 2017, 12(12): 956-958.
|
| [24] |
姚陈果，赵亚军，李成祥, 等. 不可逆电穿孔微创消融肿瘤技术的研究进展[J]. 高电压技术, 2014, 40(12): 3725-3737.
|
| [25] |
Li L, Zhang J, Liu X, et al. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(1): 51-58.
|
| [26] |
郑加生. 影像引导肿瘤消融治疗学[M]. 第一版. 北京: 人民卫生出版社. 2013: 14-16.
|
| [27] |
Long J, Zheng JS, Sun B, et al.Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study[J]. Hepatol Int, 2016, 10(1): 175-184.
|
| [28] |
Yuan C, Yuan Z, Cui X, et al. Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma[J]. J Cancer Res Ther, 2019, 15(4): 784-792.
|
| [29] |
Zheng JS, Long J, Sun B, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation?[J]. Clin Radiol, 2014, 69(6): e253-263.
|
| [30] |
Izzo F, Granata V, Grassi R, et al. Radiofrequency Ablation and Microwave Ablation inLiverTumors: An Update[J]. Oncologist, 2019, 24(10): e990-e1005.
|
| [31] |
Kalra N, Gupta P, Gorsi U, et al. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience[J].Cardiovasc InterventRadiol, 2019, 42(4): 584-590.
|
| [32] |
Li W, Wang Y, Gao W, et al. HCCwith tumor thrombus entering the right atrium and inferior vena cava treated by percutaneous ablation[J]. BMC Surg, 2017, 17(1): 17-21.
|
| [33] |
中国抗癌协会肝癌专业委员会，中国抗癌协会临床肿瘤学协作专业委员会，中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识[J]. 肿瘤, 2011, 31(5): 385-388.
|
| [34] |
Yuan Z, Wang Y, Hu C, et al. Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival[J]. Technol Cancer Res Treat, 2018, 1(17): 1533033818801362.
|
| [35] |
中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 介入放射学杂志, 2018, 27(12): 1117-1126.
|
| [36] |
韩冬，徐咏梅，于洁, 等. 大柴胡汤合六君子汤加减防治肝癌栓塞后综合征的临床研究[J], 北京中医药, 2011, 30(11): 842-843.
|
| [37] |
杨海宁. 中医调肝理脾法防治原发性肝癌经动脉灌注化疗栓塞术后综合征的疗效评价[D]. 北京, 首都医科大学, 2017.
|
| [38] |
肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J]. 肿瘤, 2014, 34(4): 295-302.
|
| [39] |
Waziry R,Hajarizadeh B, Grebely J,et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression[J]. J Hepatol, 2017, 67(6): 1204-1212.
|